PTSD Patients See Long-Term Improvements With Vagus Nerve Stimulation, Study Finds
Research suggests that pairing talk therapy with a tiny vagus nerve implant could lead to long-lasting benefits for PTSD patients
For people living with treatment-resistant PTSD, the search for relief can feel endless. A recent study suggests a tiny implant that stimulates the vagus nerve — paired with talk therapy — may deliver something rare in this field: lasting improvement that holds up six months after treatment ends.
Every participant in the small first-in-human trial lost their PTSD diagnosis. The findings, while early, are now pushing researchers to design a larger, controlled trial.
How vagus nerve stimulation works for PTSD
The 2025 study, published in Brain Stimulation, followed nine people with moderate to severe treatment-resistant PTSD. Each received a standard 12-session course of prolonged exposure (PE) therapy combined with vagus nerve stimulation, or VNS.
Woman's World Answers
Researchers used a next-generation miniaturized device. An implantable pulse generator was placed inside a silicone cuff on the left cervical vagus nerve. During therapy sessions, an external power and communication module sat over the implant inside a soft cloth collar, wirelessly powering the device — which meant no implanted battery was required. A smartphone controlled the stimulation and recorded audio for at-home exercises.
Unlike medications that continuously alter brain chemistry, the stimulation was delivered only at key moments. Brief bursts were timed to coincide with imaginal exposure exercises, when participants revisited traumatic memories, and in vivo exercises, when they confronted real-world situations tied to trauma-related fear.
Scientists believe the approach works by engaging neuromodulatory systems in the brain — particularly pathways involving norepinephrine and acetylcholine, neurotransmitters tied to attention, memory consolidation and neuroplasticity. Activating those pathways may reinforce the learning that happens during exposure therapy, helping patients form new emotional associations with traumatic memories instead of reliving them as immediate threats.
What the PTSD study found
The results were striking for a trial of this size.
“VNS therapy resulted in significant, clinically-meaningful improvements in multiple metrics of PTSD symptoms and severity compared to baseline (CAPS-5, PCL-5, and HADS all p < 0.001 after therapy). These benefits persisted at 6 months after the cessation of therapy, suggesting lasting improvements. All participants showed loss of PTSD diagnosis after completing treatment. No serious or unexpected device-related adverse events were observed,” the study said.
Assessments were performed before therapy, one week after, and at one, three and six months following the final session.
Researchers also pointed to a broader track record for the technology. VNS has been FDA approved for major depressive disorder since 2005, and thousands of people have already received conventional VNS implants for MDD. That history, the authors noted, “highlights the appetite for implanted neuromodulation approaches for serious psychiatric disorders.”
Why the findings come with caveats
The authors were direct about the limits of the trial.
“Two major limitations of this study merit consideration: the single arm design and open-label implementation of VNS therapy,” the study reads. With no sham-stimulation control group, and with outcomes drawn largely from self- and clinician-administered surveys, the design leaves room for bias. Prolonged exposure therapy alone is also known to help some patients, and the authors said they “cannot conclusively ascribe benefits to the addition of VNS.”
They argue the results “should be evaluated in a more rigorous double-blinded, placebo-controlled crossover study design that directly compares active and sham stimulation with PE.”
Future work, the team wrote, should expand the sample size and explore biomarkers that could help tailor stimulation to individual patients.
What this means for PTSD treatment going forward
The trial is part of a wider push to develop therapies that target the body’s stress-response systems. A separate clinical study of 63 veterans with a history of PTSD examined the Apollo Wearable System, a device that delivers gentle vibroacoustic stimulation and was studied for its effect on heart rate variability, a marker of autonomic nervous system function.
That wearable operates differently from an implanted vagus nerve stimulator and was not designed to treat PTSD symptoms directly. But together, the research reflects growing recognition that PTSD affects not just psychological processes but the biological systems behind stress, arousal and emotional regulation — and that targeting those systems may open new doors for patients who have run out of options.
Conversation
All comments are subject to our Community Guidelines. Woman's World does not endorse the opinions and views shared by our readers in our comment sections. Our comments section is a place where readers can engage in healthy, productive, lively, and respectful discussions. Offensive language, hate speech, personal attacks, and/or defamatory statements are not permitted. Advertising or spam is also prohibited.
